Can Removing Fallopian Tubes Reduce Ovarian Cancer Risk? SUMMARY: Ovarian cancer has a poor survival rate, with only 50% of women living five years beyond diagnosis. There is no effective screening test and symptoms are often hard to spot, leading to late diagnosis.

Ovarian cancer remains one of the most lethal gynecologic malignancies, with a five‑year survival rate of only about 50 %. The disease is notoriously difficult to detect early because there is no reliable screening test and the symptoms—such as abdominal bloating, pelvic pain, and changes in urinary habits—are often vague and easily attributed to other conditions. As a result, most cases are diagnosed at an advanced stage when the cancer has already spread beyond the ovaries.

The lack of early detection tools and subtle early signs contributes to the high mortality rate. While research continues to explore potential biomarkers and imaging techniques, current diagnostic strategies rely on a combination of pelvic examinations, transvaginal ultrasound, and CA‑125 blood tests, which are most useful after symptoms prompt investigation. Early-stage disease is treatable with surgery and chemotherapy, but the late presentation of most patients limits the effectiveness of these interventions.

Efforts to improve outcomes focus on raising awareness of risk factors—such as age, family history, and genetic mutations like BRCA1 and BRCA2—and encouraging prompt medical evaluation of persistent symptoms. Until a proven screening method becomes available, early recognition of warning signs remains the most critical step in reducing ovarian cancer mortality.